ARQT vs KLAC · rev $235.3M vs P/E 55, rev $13.58B
Arcutis Biotherapeutics Inc (ARQT) versus KLA Corporation (KLAC) — a side-by-side from cached financials, not a winner call.
Arcutis Biotherapeutics Inc (ARQT) is a biotechnology company listed on US.
KLA Corporation (KLAC) is a semiconductor equipment & materials company listed on US.
Latest reported ARQT revenue for 2026-06-30 was $235.3M. Net income was $3.7M. ARQT currently screens at market cap $1.64B.
Latest reported KLAC revenue for 2026-06-30 was $13.58B. Net income was $4.83B. Revenue was up 11.7% from 2025-06-30 to 2026-06-30. KLAC currently screens at market cap $252.01B and trailing P/E 54.7.
ARQT currently screens at market cap $1.64B. KLAC currently screens at market cap $252.01B and trailing P/E 54.7.
Not investment advice. Open the ARQT and KLAC stock pages for the full models.
Not investment advice.